Cargando…
A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge
To curb the pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), multiple platforms have been employed toward a safe and highly effective vaccine. Here, we develop a novel cell-based vaccine candidate, namely K562-S, by utilizing...
Autores principales: | He, Xiangchuan, Ding, Longfei, Cao, Kangli, Peng, Haoran, Gu, Chenjian, Li, Yutang, Li, Duoduo, Dong, Lanlan, Hong, Xiujing, Wang, Xiangwei, Fu, Meilan, Qiu, Chenli, Zhu, Cuisong, Zhang, Ziling, Song, Shu, Wang, Chenguang, Jiang, Zhengfan, Xie, Youhua, Qi, Zhongtian, Zhao, Chen, Zhao, Ping, Zhang, Xiaoyan, Xu, Jianqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366622/ https://www.ncbi.nlm.nih.gov/pubmed/34304724 http://dx.doi.org/10.1080/22221751.2021.1957400 |
Ejemplares similares
-
A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice
por: Cao, Kangli, et al.
Publicado: (2022) -
Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020) -
Renaming the SARS‐CoV‐2 Omicron sublineages as SARS‐CoV‐3 is contrary to nomenclature standards based on evolutionary and serological evidence
por: Qi, Zhongtian, et al.
Publicado: (2022) -
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV
por: Jiang, Wen, et al.
Publicado: (2021) -
Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV
por: Goyal, Rajat, et al.
Publicado: (2022)